Clinical Trial Detail

NCT ID NCT03106077
Title Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Mirvetuximab Soravtansine

Age Groups: adult senior

No variant requirements are available.